Pemivibart

Monoclonal antibody for COVID-19

US DailyMed: Pemivibart

Routes of
administrationIntravenousATC code

None

Legal statusLegal status

US: ℞-only via EUA^[1]^[2]

IdentifiersCAS Number

2858673-18-2

UNII

557S3L3FAP

KEGG

D12876

Pemivibart, sold under the brand name Pemgarda, is a monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID‑19.^[3]

The US Food and Drug Administration (FDA) issued an emergency use authorization for pemivibart in March 2024.^[3]^[4]

Medical uses

In the US, pemivibart is authorized for the pre-exposure prophylaxis (prevention) of COVID‑19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms (88 lb).^[3] It is authorized for individuals who are not currently infected with SARS‑CoV‑2 and who have not had a known recent exposure to an individual infected with SARS‑CoV‑2; and who have moderate-to-severe immune compromise due to a medical condition or due to taking immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID‑19 vaccination.^[3]

Society and culture

Names

Pemivibart is the international nonproprietary name.^[5]

References

^ "Emergency Use Authorization: PEMGARDA (pemivibart)". U.S. Food and Drug Administration. 22 March 2024.
^ "Highlight of Emergency Use Authorization: PEMGARDA (pemivibart)". U.S. Food and Drug Administration. Archived from the original on 23 March 2024. Retrieved 23 March 2024.
^ ^a ^b ^c ^d "FDA Roundup: March 22, 2024". U.S. Food and Drug Administration (FDA). 22 March 2024. Archived from the original on 23 March 2024. Retrieved 23 March 2024. This article incorporates text from this source, which is in the public domain.
^ "Invivyd Announces FDA Authorization for Emergency Use of Pemgarda (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19" (Press release). Invivyd. 22 March 2024. Archived from the original on 23 March 2024. Retrieved 23 March 2024 – via GlobeNewswire.
^ World Health Organization (2023). "INN Proposed International Nonproprietary Names: List 129". WHO Drug Information. 37 (2): 265–571. hdl:10665/371789.

This article incorporates public domain material from the United States Department of Health and Human Services

Monoclonal antibodies for infectious disease and toxins

Fungal

Human	Efungumab^†

Viral

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab^§ Bamlanivimab^† (+etesevimab)^† Bebtelovimab^§ Casirivimab^† (+imdevimab) Cilgavimab^† (+tixagevimab)^† Diridavumab^§ Etesevimab^† Exbivirumab^§ Foravirumab^§ Imdevimab^† (+casirivimab) Libivirumab^§ Maftivimab Nirsevimab^† Odesivimab Pemivibart Rafivirumab^§ Regavirumab^§ Regdanvimab Sevirumab^† Sotrovimab Suptavumab Tixagevimab^† (+cilgavimab)^† Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab^†
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§